WuXi Biologics (Cayman) PEG Ratio

WuXi Biologics (Cayman) (2269.HK) currently reports a PEG ratio of 1203.87. That is above the Healthcare sector average of 11.77. Use the charts on this page to explore WuXi Biologics (Cayman)'s PEG ratio history and peer comparisons.

WuXi Biologics (Cayman)'s PEG ratio of 1203.87 is higher than the Healthcare sector average of 11.77. That is roughly 10126.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates WuXi Biologics (Cayman)'s market price to a fundamental measure such as earnings, sales, or book value. At 1203.87, 2269.HK can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 1203.87, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.77. From there, open related valuation or income-statement pages for WuXi Biologics (Cayman), and consider following 2269.HK for alerts when major investors trade the stock.

WuXi Biologics (Cayman) is classified in the Healthcare sector. On PEG ratio, it currently shows 1203.87 versus a sector average near 11.77. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 2269.HK with unrelated industries.